These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 22825126)

  • 21. Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.
    Li XQ; Ouyang ZG; Zhang SH; Liu H; Shang Y; Li Y; Zhen YS
    J Neurooncol; 2014 Aug; 119(1):91-100. PubMed ID: 24842385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas.
    Moroz MA; Huang R; Kochetkov T; Shi W; Thaler H; de Stanchina E; Gamez I; Ryan RP; Blasberg RG
    Clin Cancer Res; 2011 May; 17(10):3282-92. PubMed ID: 21385926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
    Ryu CH; Yoon WS; Park KY; Kim SM; Lim JY; Woo JS; Jeong CH; Hou Y; Jeun SS
    J Biomed Biotechnol; 2012; 2012():987495. PubMed ID: 22701311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
    Grossman R; Tyler B; Rudek MA; Kim E; Zadnik P; Khan U; Blakeley JO; Pathak AP; Brem H
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):93-100. PubMed ID: 23649683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Local delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growth.
    Benny O; Menon LG; Ariel G; Goren E; Kim SK; Stewman C; Black PM; Carroll RS; Machluf M
    Clin Cancer Res; 2009 Feb; 15(4):1222-31. PubMed ID: 19190128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.
    Ulasov IV; Sonabend AM; Nandi S; Khramtsov A; Han Y; Lesniak MS
    Br J Cancer; 2009 Apr; 100(7):1154-64. PubMed ID: 19277041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
    Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2.
    Zhang X; Yu J; Zhao C; Ren H; Yuan Z; Zhang B; Zhuang J; Wang J; Feng B
    Biomed Pharmacother; 2019 Jan; 109():2192-2202. PubMed ID: 30551476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
    Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene expression profiling predicts response to temozolomide in malignant gliomas.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
    Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
    Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death.
    Cheng Y; Sk UH; Zhang Y; Ren X; Zhang L; Huber-Keener KJ; Sun YW; Liao J; Amin S; Sharma AK; Yang JM
    PLoS One; 2012; 7(4):e35104. PubMed ID: 22496897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Andrographolide sensitizes glioma to temozolomide by inhibiting DKK1 expression.
    Zhang ZS; Gao ZX; He JJ; Ma C; Tao HT; Zhu FY; Cheng YN; Xie CQ; Li JQ; Liu ZZ; Hou LL; Sun H; Xie SQ; Fang D
    Br J Cancer; 2024 Nov; 131(8):1387-1398. PubMed ID: 39266624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Intranasal administration of temozolomide for brain-targeting delivery: therapeutic effect on glioma in rats].
    Li Y; Gao Y; Liu G; Zhou X; Wang Y; Wang Y; Ma L
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 May; 34(5):631-5. PubMed ID: 24849425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.
    Gong A; Ge N; Yao W; Lu L; Liang H
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):531-8. PubMed ID: 25047724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
    Grossman R; Brastianos H; Blakeley JO; Mangraviti A; Lal B; Zadnik P; Hwang L; Wicks RT; Goodwin RC; Brem H; Tyler B
    J Neurooncol; 2014 Jan; 116(1):59-65. PubMed ID: 24185441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts.
    Adhikari B; Li J; Brandel MG; Futalan D; Akers J; Deming T; Chen CC; Carter BS
    J Clin Neurosci; 2017 Nov; 45():288-292. PubMed ID: 28867360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
    Hayashi T; Adachi K; Ohba S; Hirose Y
    J Neurooncol; 2013 Nov; 115(2):169-78. PubMed ID: 23943501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
    Rocha CR; Kajitani GS; Quinet A; Fortunato RS; Menck CF
    Oncotarget; 2016 Jul; 7(30):48081-48092. PubMed ID: 27344172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.